ICVX

Icosavax, Inc. [ICVX] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

ICVX Stock Summary

Top ICVX Correlated Resources

ICVX


Top 10 Correlated ETFs

ICVX


Top 10 Correlated Stocks

ICVX


In the News

11:16 10 Dec 2023 ICVX

Wall Street Analysts Believe Icosavax, Inc. (ICVX) Could Rally 175.87%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 175.9% in Icosavax, Inc. (ICVX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

10:34 10 Dec 2023 ICVX

Icosavax, Inc. (ICVX) is on the Move, Here's Why the Trend Could be Sustainable

Icosavax, Inc. (ICVX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

08:00 10 Dec 2023 ICVX

Icosavax to Participate in the Cantor Fitzgerald Global Healthcare Conference 2023

SEATTLE, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced that the company will participate in the Cantor Fitzgerald Global Healthcare Conference 2023, taking place from September 26-28, 2023 in New York City.

12:43 10 Dec 2023 ICVX

Icosavax (ICVX) Up on Positive VLP Vaccine Candidate Data

Icosavax (ICVX) surges on positive data from the clinical study of IVX-A12, targeting respiratory syncytial virus and human metapneumovirus in older adults.

12:17 10 Dec 2023 ICVX

Why Shares of Icosavax Jumped on Tuesday

Icosavax also initiated a $67.8 million stock sale. The biopharmaceutical company's pipeline also includes vaccines to treat influenza and severe acute respiratory syndrome coronavirus.

12:11 10 Dec 2023 ICVX

Should You Buy Icosavax (ICVX) Ahead of Earnings?

Icosavax (ICVX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

06:59 10 Dec 2023 ICVX

Icosavax, Inc. (ICVX) Reports Q1 Loss, Lags Revenue Estimates

Icosavax, Inc. (ICVX) came out with a quarterly loss of $0.60 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.60 per share a year ago.

09:46 10 Dec 2023 ICVX

3 Biotech Stocks to Watch for Potential Breakthroughs

Biotech stock fortunes hinge upon potential, progress, and the ultimate realization of drugs and devices that treat diseases. Stringent regulatory processes and long development times result in substantial costs.

08:18 10 Dec 2023 ICVX

Icosavax (ICVX) Up 112% on Upbeat Data From RSV Jab Study

Data from an early-stage study showed that Icosavax's (ICVX) investigational RSV vaccine exhibited sustained immunologic response following six months of dose administration.

09:03 10 Dec 2023 ICVX

Icosavax, Inc. (ICVX) Reports Q3 Loss, Lags Revenue Estimates

Icosavax, Inc. (ICVX) delivered earnings and revenue surprises of 3.51% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ICVX Financial details

Company Rating
Neutral
Market Cap
526.45M
Income
-92.62M
Revenue
0
Book val./share
4.64
Cash/share
4.58
Dividend
-
Dividend %
-
Employees
60
Optionable
No
Shortable
Yes
Earnings
04 Apr 2024
P/E
-5.68
Forward P/E
-5.42
PEG
1.29
P/S
-
P/B
2.26
P/C
2.29
P/FCF
-7.14
Quick Ratio
17.59
Current Ratio
18.06
Debt / Equity
0.03
LT Debt / Equity
0.03
-
-
EPS (TTM)
-2.12
EPS next Y
-1.94
EPS next Q
-0.58
EPS this Y
-41.01%
EPS next Y
-8.3%
EPS next 5Y
12.26%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-25.42%
-
-
-
-
SMA20
51.9%
SMA50
28.11%
SMA100
9.25%
Inst Own
59.27%
Inst Trans
0.57%
ROA
-37%
ROE
-41%
ROC
-0.44%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
50.09M
Shs Float
32.5M
-
-
-
-
Target Price
27
52W Range
3.505-16.45
52W High
-34.31%
52W Low
+250.33%
RSI
60.1
Rel Volume
1.43
Avg Volume
316K
Volume
452.88K
Perf Week
2.74%
Perf Month
71.73%
Perf Quarter
7.46%
Perf Half Y
5%
-
-
-
-
Beta
1.064
-
-
Volatility
0.34%, 1.85%
Prev Close
4.79%
Price
10.51
Change
2.04%

ICVX Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K
Revenue per share
0000
Net income per share
-0.51-6.67-3.78-2.23
Operating cash flow per share
-0.45-4.94-2.15-1.55
Free cash flow per share
-0.45-4.94-2.2-1.83
Cash per share
2.254.5615.535.5
Book value per share
-0.8-9.2815.495.49
Tangible book value per share
-0.8-9.2815.495.49
Share holders equity per share
-0.8-9.2815.495.49
Interest debt per share
01.830.010.14
Market cap
358.11M100.65M411.06M315.42M
Enterprise value
335.03M92.48M131.98M265.37M
P/E ratio
-68.92-5.25-6.05-3.57
Price to sales ratio
0000
POCF ratio
-78.38-7.08-10.67-5.11
PFCF ratio
-78.38-7.08-10.39-4.33
P/B Ratio
-43.44-3.771.481.45
PTB ratio
-43.44-3.771.481.45
EV to sales
0000
Enterprise value over EBITDA
-62.07-4.94-2.03-2.79
EV to operating cash flow
-73.33-6.51-3.42-4.3
EV to free cash flow
-73.33-6.5-3.34-3.65
Earnings yield
-0.01-0.19-0.17-0.28
Free cash flow yield
-0.01-0.14-0.1-0.23
Debt to equity
0-0.1900.04
Debt to assets
00.3100.04
Net debt to EBITDA
4.280.444.30.53
Current ratio
19.042.7731.0216.24
Interest coverage
0-56.53-436.1728.81
Income quality
0.860.750.580.67
Dividend Yield
0000
Payout ratio
0000
Sales general and administrative to revenue
0000
Research and developement to revenue
0000
Intangibles to total assets
0000
Capex to operating cash flow
000.030.18
Capex to revenue
0000
Capex to depreciation
0-11-12.27-12.92
Stock based compensation to revenue
0000
Graham number
3.0337.336.3216.59
ROIC
0.640.88-0.24-0.39
Return on tangible assets
-0.22-1.19-0.24-0.37
Graham Net
-0.83-10.3415.014.98
Working capital
22.07M10.33M277.32M210.13M
Tangible asset value
-8.24M-26.7M278.22M218.16M
Net current asset value
-8.24M-26.71M277.14M203.4M
Invested capital
0-0.1900.04
Average receivables
0000
Average payables
01.36M2.91M3.4M
Average inventory
0000
Days sales outstanding
0000
Days payables outstanding
0000
Days of inventory on hand
0000
Receivables turnover
0000
Payables turnover
0000
Inventory turnover
0000
ROE
0.630.72-0.24-0.41
Capex per share
00-0.06-0.28

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-0.52-0.54-0.55-0.59-0.44
Operating cash flow per share
-0.44-0.23-0.52-0.43-0.38
Free cash flow per share
-0.54-0.29-0.56-0.44-0.38
Cash per share
5.575.484.765.524.58
Book value per share
5.685.484.855.534.64
Tangible book value per share
5.685.484.855.534.64
Share holders equity per share
5.685.484.855.534.64
Interest debt per share
0.20.170.20.190.16
Market cap
125.61M316.1M239.33M444.57M387.74M
Enterprise value
67.78M266.05M198.79M297.94M332.57M
P/E ratio
-1.51-3.68-2.65-4.19-4.4
Price to sales ratio
00000
POCF ratio
-7.23-35.11-11.06-23.13-20.44
PFCF ratio
-5.89-27.36-10.31-22.34-20.4
P/B Ratio
0.561.451.21.791.67
PTB ratio
0.561.451.21.791.67
EV to sales
00000
Enterprise value over EBITDA
-2.95-10.59-7.5-10.29-13.16
EV to operating cash flow
-3.9-29.55-9.18-15.5-17.53
EV to free cash flow
-3.18-23.03-8.56-14.97-17.5
Earnings yield
-0.17-0.07-0.09-0.06-0.06
Free cash flow yield
-0.17-0.04-0.1-0.04-0.05
Debt to equity
0.030.040.040.030.03
Debt to assets
0.030.040.040.030.03
Net debt to EBITDA
2.511.991.535.062.18
Current ratio
17.5516.2415.6716.7618.06
Interest coverage
-19.8311.7841.2500
Income quality
0.790.380.880.730.86
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
0.230.280.070.040
Capex to revenue
00000
Capex to depreciation
-27.66-4.12-2.45-1.02-0.04
Stock based compensation to revenue
00000
Graham number
8.188.167.738.586.79
ROIC
-0.09-0.1-0.11-0.11-0.1
Return on tangible assets
-0.09-0.09-0.11-0.1-0.09
Graham Net
5.114.974.565.044.2
Working capital
215.7M210.13M189.27M236.69M222.28M
Tangible asset value
225.66M218.16M200.08M247.72M232.38M
Net current asset value
210.52M203.4M193.58M230.4M216.39M
Invested capital
0.030.040.040.030.03
Average receivables
00000
Average payables
4.1M3.81M2.25M1.58M1.39M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.09-0.1-0.11-0.11-0.09
Capex per share
-0.1-0.06-0.04-0.020

ICVX Frequently Asked Questions

What is Icosavax, Inc. stock symbol ?

Icosavax, Inc. is a US stock , located in Seattle of Wa and trading under the symbol ICVX

Is Icosavax, Inc. buy or a sell ?

1 stock analysts have 1 predictions with a medium analyst target price of $27. The lowest prediction is $27 and the highest is $27

What is ICVX stock prediction ?

What is Icosavax, Inc. stock quote today ?

Icosavax, Inc. stock price is $10.51 today.

Is Icosavax, Inc. stock public?

Yes, Icosavax, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap